WO2003011335A2 - Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung - Google Patents
Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung Download PDFInfo
- Publication number
- WO2003011335A2 WO2003011335A2 PCT/EP2002/008360 EP0208360W WO03011335A2 WO 2003011335 A2 WO2003011335 A2 WO 2003011335A2 EP 0208360 W EP0208360 W EP 0208360W WO 03011335 A2 WO03011335 A2 WO 03011335A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- vaccine
- papillomavirus
- structural protein
- coding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the invention relates to polyvalent vaccines against diseases caused by papillomaviruses, processes for their production and their use.
- Papillomaviruses form a subfamily of papovaviruses with more than 80 genotypes. Infection with papilloma viruses can lead to warts, papillomas, acanthomas, skin and cervical carcinomas. A single disease can be caused by different types of papillomavirus.
- HPV human pathogenic papillomaviruses
- Vaccines for the effective prevention of HPV-related diseases must always contain a mixture of different virus types in order to achieve comprehensive protection. However, the preparation of such vaccines is difficult due to the fact described above that the same disease can be caused by different types of HPV.
- the present invention is therefore based on the object of providing a vaccine and a method for its simple production, with which an immune response against various types of HPV can be obtained.
- Mammals are injected with one or more expression vector (s) which have the DNA coding for a structural protein of papillomavirus (PV) or a fragment thereof, with at least some of the expression vectors being random in the coding DNA generated heterologous sequences are used,
- fragments thereof indicates that the DNA encodes a protein that is shorter in comparison to the wild-type protein, but the properties required for the present invention, in particular chemical, physical and / or functional properties.
- the gene coding for PV capsids of a certain type can be modified by inserting randomly generated sequences.
- recombinant vectors such as plasmids
- sera are prepared by immunization with a plurality of L1 expression vectors, which can be referred to as pools of expression vectors, which are then tested for reactivity with capsids of different PV types. Only then are the pools separated and capside with cross-neutralizing epitopes identified.
- the vaccine according to the invention can be VLPs (virus-like particies) or capsomers which contain modified L1 proteins which may have epitopes which are neutralizing against cancer. H. which lead to an antibody response directed against different PV types.
- VLPs virus-like particies
- capsomers which contain modified L1 proteins which may have epitopes which are neutralizing against cancer. H. which lead to an antibody response directed against different PV types.
- Such vaccines can be referred to as polyvalent vaccines that can be used against infections with various types of PV.
- VLP virus-like particles
- Epitope is another name for antigen determinants. These are areas on the surface of an antigen to which a specific antibody binds via its antigen-binding region.
- a randomly generated heterologous sequence is used in a main structural protein, such as the L1 gene, of a certain type of a papillomavirus, in particular in the hypervariable regions of L1 genes.
- insert in the sense of the present invention indicates that the randomly generated heterologous sequences can be present in addition to the naturally occurring epitopes in the gene for the structural protein and / or the naturally occurring epitope in the gene for the structural protein by a randomly generated heterologous Sequence can be exchanged.
- an L1 gene cassette is described below, which makes it possible to insert different, randomly generated oligonucleotides into the hypervariable regions of the L1 structural protein.
- a gene cassette can first be constructed for inserting the randomly generated oligonucleotides into the DNA sequence of the L1 structural protein.
- This gene cassette is characterized in that, for example, the DNA coding for the hypervariable regions of the L1 structural protein is modified in such a way that silent mutations insert monovalent interfaces for restriction endonucleases which flank these hypervariable regions.
- silent mutation is a term for the introduction of an altered DNA sequence that bears a recognition site for a specific restriction endonuclease without the amino acid sequence being changed thereby.
- the term monovalent interface denotes a recognition sequence for a restriction endonuclease that occurs only once in the DNA sequence that codes for the target protein. For technical reasons, this is a recognition sequence for a restriction enzyme, which must not be present in the plasmid used for the preparation of the variable DNA mixtures.
- the heterologous, randomly degenerate oligonucleotides can be constructed such that they are also flanked by the monovalent interfaces as they flank the hypervariable regions of the L1 DNA sequence. As a result, the gene cassette (in a cloning plasmid) and the oligonucleotides can be treated with the corresponding restriction enzymes. The oligonucleotides can then be ligated into the gene cassette.
- heterologous sequences indicates a DNA sequence of any kind, that of the DNA sequence coding for the naturally occurring epitopes in the structural protein of PV in at least one to at most all nucleotides This can be achieved by exchanging nucleotides Since epitopes generally only comprise a few amino acids in the order of magnitude of oligoproteins, the heterologous sequences can be produced in the usual way, for example by oligonucleotide synthesis, starting from the DNA sequences of the known epitopes ,
- the corresponding DNA sequence consists of 36 nucleotides. From these, one to at most all of the nucleotides can be exchanged for the randomly generated heterologous sequence. Since one nucleotide can be replaced by a total of three other dq of different nucleotides, the random generation of the DNA sequences can result in a multitude of up to several thousand new DNA sequences which are heterologous to the original DNA sequence. Since the production of this DNA is not targeted, as is the case, for example, when only a specific nucleotide in a DNA sequence is exchanged, it can be referred to as a randomly generated DNA sequence.
- a so-called “random library” is an example of a collection of different heterologous, randomly generated sequences.
- the randomly generated heterologous DNA sequences used to produce the vaccine according to the invention are therefore those which are not generated by targeted mutations, but rather, based on known epitope sequences, at least one nucleotide and at most all nucleotides are randomly generated by one of the three other conceivable nucleotides, which results in a randomly generated collection of different DNA sequences. It is favorable if the randomly generated heterologous DNA sequence is based on the naturally occurring epitopes with regard to the number of nucleotides, ideally even has the same number of nucleotides.
- the oligonucleotides can be produced using the method of oligonucleotide synthesis.
- the nucleotide sequence is generated linearly, i.e. the chain extension takes place through the reaction of the already existing nucleotide sequence with an activated precursor of the following nucleotide.
- an activated precursor of the following nucleotide not only the activated precursor of a nucleotide but also activated precursors of 2, 3 or 4 nucleotides can be used for the production of degenerate oligonucleotides. This creates mixtures of oligonucleotides that code for several different amino acids at this point.
- DNA sequences that do not occur in PV pathogens that are pathogenic to humans, as well as the sequences coding for the wild-type epitopes.
- the sequence range from amino acid 130 to 152 can apply to the main structural protein L1 as an example.
- a DNA sequence of 69 nucleotides encodes the 23 amino acids of this sequence section.
- the additional introduction of the monovalent interfaces creates DNA sequences with over 80 nucleotides. Alternatively, the range from amino acid 260-299 or amino acid 349-360 can also be selected.
- the counter strand can be synthesized by different filling reactions with DNA polymerases.
- the double-stranded DNA obtained in this way can then be modified directly with the corresponding restriction endonucleases and ligated into the L1 gene cassette.
- the person skilled in the art can first ligate the double-stranded DNA sequences via "blunt end” cloning in cloning vectors. The DNA sequences can then be cloned from these "random libraries" into the L1 gene cassettes with high efficiencies.
- the randomly generated heterologous DNA sequences are then, as described above, inserted into the genes of the structural proteins of PV, in particular into the L1 genes of papilloma viruses of a certain type.
- Papilloma viruses are represented by HPV, BPV and CRPV.
- the insertion into the hypervariable regions of L1 genes takes place.
- the invention is described here with reference to the preferred structural protein gene L1, but is not limited to this.
- the length of the heterologous DNA used i.e. the number of nucleotides, as already mentioned above, is based on the length of the naturally occurring epitopes. Above all, it is chosen so that the formation of the capsomeres and the VLPs is not impaired.
- the original epitopes of the L1 gene are replaced by the randomly generated heterologous DNA sequences, only one of the epitopes can be replaced. However, several, up to all of the maximum possible epitopes in the L1 gene can also be replaced by randomly generated heterologous sequences.
- the L1 genes in which the randomly generated heterologous sequences are inserted can subsequently be cloned into eukaryotic expression vectors. This can result in a large number of bacterial clones, and subgroups can then be formed from this large number of bacterial clones, i.e. cloning this large number of bacteria is divided into pools of several thousand bacterial clones and further used for the production of the vaccine according to the invention.
- mammals are injected with one or more expression vectors which can be characterized as described above.
- the term “several” indicates that a pool of expression vectors can be used, which can contain up to 10,000, in particular up to 5,000, different expression vectors from one another.
- the differences in the expression vectors consist in particular in the randomly generated cloned-in one heterologous DNA.As can be seen from the above explanations of the randomly generated heterologous DNA, the expression vectors can also contain DNA sequences which were obtained during the random generation of the DNA sequences, but - because the generation is just random - with the DNA Sequence is identical for the wild-type epitopes. Accordingly, expression vectors are injected into the mammals in which at least a part to a maximum of all heterologous DNA sequences randomly generated in the coding DNA are used.
- DNA vaccination genetic immunization
- This is a known method for immunization, which, in contrast to conventional immunization, does not inject antigens, but rather the coding DNA in an appropriate expression vector.
- the intramuscular form of application has proven to be beneficial for DNA vaccination, since the gene obviously takes up and expresses the cell before the DNA is broken down. The immune reaction then takes place against the expressed protein.
- An advantage of DNA vaccination can be seen in particular in the fact that the virus particles no longer have to be prepared and purified beforehand, for example by expression of the L1 gene using recombinant vectors. DNA vaccination can thus be carried out in a simple and quick manner.
- This DNA vaccination can be carried out in mammals such as rats, mice, hamsters and guinea pigs.
- Sera can then be obtained from the experimental animals in a conventional manner and tested for reactivity with different types of papillomavirus. This can be done for example by means of ELISA, which are specific for papillomavirus types.
- DNA pools used for DNA vaccination which elicit an immune response against various types of papillomavirus, can subsequently be isolated and in turn analyzed by DNA. This enables those clones to be identified which code for VLPs or capsomers which have cross-neutralizing epitopes. These are epitopes that lead to an antibody response against various types of papillomavirus.
- the corresponding DNA clones can then be further examined by conventional genetic engineering methods and, if necessary, the corresponding virus particles can be produced, isolated and purified.
- the L1 molecules can be expressed, VLPs or capsomers can be produced and the immunity of the cleaned particles can be examined.
- the vaccine according to the invention is therefore a multivalent vaccine which induces immune protection against diseases caused by different types of PV.
- the papillomavirus is a human-pathogenic papillomavirus. This makes it possible to treat diseases in humans caused by human pathogenic papillomaviruses with the vaccine according to the invention.
- the structural protein is L1, since this is particularly well suited for the production of the vaccine according to the invention.
- the structural protein forms DNA-free virus capsids or capsomers.
- the present invention furthermore relates to a DNA vaccine comprising one or more expression vector (s) which have the DNA coding for a structural protein of papillomavirus or a fragment thereof, at least some of the expression vectors being incorporated into the coding DNA randomly generated heterologous sequences are used.
- the structural protein gene is expressed and the immunization is then carried out against the expressed protein. Immunization is achieved in a particularly simple manner in this way.
- the present invention also relates to a method for producing the above-described vaccine, wherein
- Mammals are injected with one or more expression vector (s) which have the DNA coding for a structural protein of papillomavirus or a fragment thereof, with at least some of the expression vectors in the coding DNA randomly generated heterologous sequences are used,
- the process according to the invention is characterized in that the modified genes of the structural proteins (insertion of randomly generated heterologous DNA) no longer have to be individually checked for their ability to form VLPs or capsomers before the immunization. Rather, pools of recombinant DNA expression vectors are used to immunize mammals, especially mice. The sera obtained are examined for the presence of antibodies against particles of different types of papillomavirus, in particular types of HPV. If the reaction is positive, i.e. if cross-neutralizing epitopes are detected can, the pools of expression vectors are isolated and the corresponding proteins are analyzed.
- This method according to the invention enables a large number of variants of papillomavirus particles, in particular capsids, to be examined for their immunogenic properties without the particles having to be individually expressed and purified beforehand by expression of the mutated structural protein. Furthermore, the method according to the invention enables highly effective, multivalent papillomavirus vaccines to be produced in a quick, simple and inexpensive manner.
- the vaccine according to the invention is particularly suitable as a polyvalent vaccine for vaccination against diseases caused by papillomavirus, in particular those diseases which are caused by different types of papillomavirus. Examples of these diseases are warts, papillomas, acanthomas, skin and cervical carcinomas.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02791474A EP1411981A2 (de) | 2001-07-30 | 2002-07-26 | Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung |
US10/485,454 US7320861B2 (en) | 2001-07-30 | 2002-07-26 | Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
AU2002355654A AU2002355654A1 (en) | 2001-07-30 | 2002-07-26 | Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
US10/778,936 US7354714B2 (en) | 2001-07-30 | 2004-02-13 | Production and applications for polyvalent vaccines against diseases caused by papilloma viruses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10137102A DE10137102A1 (de) | 2001-07-30 | 2001-07-30 | Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung |
DE10137102.0 | 2001-07-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10485454 A-371-Of-International | 2002-07-26 | ||
US10/778,936 Continuation-In-Part US7354714B2 (en) | 2001-07-30 | 2004-02-13 | Production and applications for polyvalent vaccines against diseases caused by papilloma viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011335A2 true WO2003011335A2 (de) | 2003-02-13 |
WO2003011335A3 WO2003011335A3 (de) | 2003-11-06 |
Family
ID=7693601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/008360 WO2003011335A2 (de) | 2001-07-30 | 2002-07-26 | Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung |
Country Status (5)
Country | Link |
---|---|
US (2) | US7320861B2 (de) |
EP (1) | EP1411981A2 (de) |
AU (1) | AU2002355654A1 (de) |
DE (1) | DE10137102A1 (de) |
WO (1) | WO2003011335A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080160040A1 (en) * | 2004-04-15 | 2008-07-03 | Ghim Shin-Je | Plant-produced compositions for treating papillomavirus infection and related methods |
EP1934335A4 (de) * | 2005-09-08 | 2010-05-05 | Large Scale Biology Corp | Modifizierte tabak-mosaikvirus-teilchen als gerüste zur anzeige von protein-antigenen für impfstoff-anwendungen |
US7445786B1 (en) | 2006-04-10 | 2008-11-04 | Manuela Rehtanz | Diagnosing and protecting against tursiops truncatus papillomavirus |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2524487B1 (fr) * | 1982-04-05 | 1985-11-22 | Pasteur Institut | Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants |
US5045447A (en) * | 1989-03-15 | 1991-09-03 | Minson Anthony C | Method of producing antibodies to HPV |
US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US6183745B1 (en) | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
US7476389B1 (en) | 1991-07-19 | 2009-01-13 | The University Of Queensland | Papillomavirus vaccines |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5302397A (en) | 1991-11-19 | 1994-04-12 | Amsden Brian G | Polymer-based drug delivery system |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US6317629B1 (en) | 1992-06-02 | 2001-11-13 | Alza Corporation | Iontophoretic drug delivery apparatus |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
DE4415743C2 (de) | 1994-05-04 | 1996-10-10 | Deutsches Krebsforsch | Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen |
US5888516A (en) | 1994-05-16 | 1999-03-30 | Merck & Co. Inc. | Recombinant papillomavirus vaccines |
CN1152935A (zh) | 1994-05-16 | 1997-06-25 | 麦克公司 | 乳头状瘤病毒疫苗 |
IL113817A (en) | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide for vaccination against the umbilical cord virus |
US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
EP1728800A1 (de) | 1994-10-07 | 2006-12-06 | Loyola University Of Chicago | Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung |
US5820870A (en) | 1995-03-22 | 1998-10-13 | Merck & Co., Inc. | Recombinant human papillomavirus type 18 vaccine |
US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US5821087A (en) | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
US6350780B1 (en) | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
US5981173A (en) | 1996-02-14 | 1999-11-09 | Institut Pasteur | Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39 |
US6245349B1 (en) | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
US6132765A (en) | 1996-04-12 | 2000-10-17 | Uroteq Inc. | Drug delivery via therapeutic hydrogels |
US6074673A (en) | 1996-04-22 | 2000-06-13 | Guillen; Manuel | Slow-release, self-absorbing, drug delivery system |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6296621B1 (en) | 1996-08-23 | 2001-10-02 | Baxter International Inc. | Receptacle for passive drug delivery |
ATE314054T1 (de) | 1996-10-25 | 2006-01-15 | Shire Lab Inc | Osmotisches verabreichungssystem für lösliche dosen |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US6086582A (en) | 1997-03-13 | 2000-07-11 | Altman; Peter A. | Cardiac drug delivery system |
ZA982950B (en) | 1997-04-08 | 1998-10-19 | Merck & Co Inc | Stabilized human papillomavirus formulations |
ES2216280T3 (es) | 1997-04-08 | 2004-10-16 | MERCK & CO., INC. | Formulaciones estabilizadas de papilomavirus humano. |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6183444B1 (en) | 1998-05-16 | 2001-02-06 | Microheart, Inc. | Drug delivery module |
US5972027A (en) | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US6083996A (en) | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
ES2255155T3 (es) | 1998-02-05 | 2006-06-16 | Biosense Webster, Inc. | Dispositivo para la administracion intracardiaca de farmacos. |
US6086912A (en) | 1998-02-11 | 2000-07-11 | Gilman; Marvin S. | Topical drug delivery system |
US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
US6309410B1 (en) | 1998-08-26 | 2001-10-30 | Advanced Bionics Corporation | Cochlear electrode with drug delivery channel and method of making same |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
AU770809B2 (en) | 1998-12-17 | 2004-03-04 | Merck Sharp & Dohme Corp. | Synthetic virus-like particles with heterologous epitopes |
US6309380B1 (en) | 1999-01-27 | 2001-10-30 | Marian L. Larson | Drug delivery via conformal film |
SI1150712T1 (sl) | 1999-02-05 | 2009-02-28 | Merck & Co Inc | Pripravek cepiva proti humanem papiloma virusu |
US6245568B1 (en) | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
US6235312B1 (en) | 1999-05-14 | 2001-05-22 | Eastman Chemical Company | Liquid crystalline phase drug delivery vehicle |
DE19925199A1 (de) * | 1999-06-01 | 2000-12-07 | Medigene Ag | Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie |
US6283947B1 (en) | 1999-07-13 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
JP4799789B2 (ja) | 1999-08-25 | 2011-10-26 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子 |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6379382B1 (en) | 2000-03-13 | 2002-04-30 | Jun Yang | Stent having cover with drug delivery capability |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
DE10059631A1 (de) * | 2000-12-01 | 2002-07-18 | Medigene Ag | T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie |
GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
-
2001
- 2001-07-30 DE DE10137102A patent/DE10137102A1/de not_active Withdrawn
-
2002
- 2002-07-26 EP EP02791474A patent/EP1411981A2/de not_active Withdrawn
- 2002-07-26 US US10/485,454 patent/US7320861B2/en not_active Expired - Fee Related
- 2002-07-26 AU AU2002355654A patent/AU2002355654A1/en not_active Abandoned
- 2002-07-26 WO PCT/EP2002/008360 patent/WO2003011335A2/de not_active Application Discontinuation
-
2004
- 2004-02-13 US US10/778,936 patent/US7354714B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
None |
Also Published As
Publication number | Publication date |
---|---|
US7354714B2 (en) | 2008-04-08 |
AU2002355654A1 (en) | 2003-02-17 |
US20050004054A1 (en) | 2005-01-06 |
WO2003011335A3 (de) | 2003-11-06 |
EP1411981A2 (de) | 2004-04-28 |
DE10137102A1 (de) | 2003-02-27 |
US20050026257A1 (en) | 2005-02-03 |
US7320861B2 (en) | 2008-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69231837T2 (de) | Antigen praesentierende ms2-huelle | |
DE60110822T2 (de) | Zubereitung zur immunisierung gegen den aids-virus | |
DE69920011T2 (de) | Rekombinantes virus-vakzin gegen das virus der venezolanischen equinen encephalitis | |
DE69731309T3 (de) | Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes | |
DE69519041T2 (de) | Dna-impfstoffe gegen rotavirusinfektionen | |
DE69529748T2 (de) | Polynukleotide vakzine gegen den papilloma virus | |
DE69734284T2 (de) | Zusammensetzung eines polynukleotidvakzins zur behandlung von atemwegs- und fortpflanzungsbezogenen erkrankungen des schweins | |
DE3751092T2 (de) | Herstellung und Immunogenität von Rotavirus-Genen mittels eines Bakulovirus-Expressionssystems. | |
DE60010921T2 (de) | Künstliche chromosomen, die die genetische information für die bildung von rekombinantem rna-virus enthalten | |
DE69814177T2 (de) | Impfstoffe mit einem ltb adjuvans | |
DE69837390T2 (de) | Rekombinanter schweine adenovirus vektor | |
DE3486110T2 (de) | ||
EP2102345B1 (de) | Rsv f-protein und seine verwendung | |
DE69034075T2 (de) | Rekombinantes poxvirus und streptokokken enthaltend ein m-protein | |
DE68924183T2 (de) | Zusammensetzung und Verfahren zum Schutz gegen durch Mikroorganismen verursachte Krankheiten. | |
DE3806565A1 (de) | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen | |
WO1991005567A1 (de) | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum | |
DE3641040C2 (de) | ||
EP0516655B1 (de) | Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine | |
DE69929530T2 (de) | Attenuierter pferdeherpesvirus | |
DE3137300A1 (de) | Zur expression von proteinen von maul- und klauen-seuchen-viren geeignetes dna-molekuel, verfahren zu seiner herstellung und seine verwendung zur erzeugung von proteinen und impfstoffen | |
WO2003011335A2 (de) | Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung | |
DE69835424T2 (de) | Boviner atmungs- und darmcoronavirus als impfstoff | |
DE3853672T2 (de) | Nichtzurückschlagende RNS-Viren. | |
DE69032787T2 (de) | Mutantes pseudorabiesvirus und dasselbe enthaltende vakzine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002791474 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002791474 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485454 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |